Characterization of a novel glucokinase activator in rat and mouse models

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Lu, Min ^a   Li, Pingping ^a   Bandyopadhyay, Gautam ^a   Lagakos, William ^a   DeWolf Jr , Walter E ^b   Alford, Taylor ^b   Chicarelli, Mark Joseph ^b   Williams, Lance ^b   Anderson, Deborah A ^b   Baer, Brian R ^b   McVean, Maralee ^b   Conn, Marion ^c   Véniant, Murielle M ^c   Coward, Peter ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b ARRAY BIOPHARMA INC   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 (3 (2,6 DIMETHYLPYRIDIN 3 YLOXY) 5 (PYRIDIN 2 YLTHIO)PYRIDIN 2 YLAMINO) 1,2,4 THIADIAZOL 3 YL)ETHANE 1,2 DIOL HYDROCHLORIDE; AGENTS AFFECTING CARBOHYDRATE METABOLISM; GKA 23; GLUCOKINASE; UNCLASSIFIED DRUG; 1-(5-(3-(2,6-DIMETHYLPYRIDIN-3-YLOXY)-5-(PYRIDIN-2-YLTHIO)PYRIDIN-2-YLAMINO)-1,2,4-THIADIAZOL-3-YL)ETHANE-1,2-DIOL; AMINOPYRIDINE DERIVATIVE; ENZYME ACTIVATOR; GLUCOSE; GLUCOSE BLOOD LEVEL; INSULIN; THIADIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ANALYSIS; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; IN VITRO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; LIPID ANALYSIS; MALE; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; RAT; ANIMAL; AREA UNDER THE CURVE; C57BL MOUSE; CATALYSIS; CHEMISTRY; CYTOLOGY; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; KINETICS; LIVER; LIVER CELL; METABOLISM; PHOSPHORYLATION; SECRETION (PROCESS); SPRAGUE DAWLEY RAT;

AMINOPYRIDINES; ANIMALS; AREA UNDER CURVE; BLOOD GLUCOSE; CATALYSIS; DIABETES MELLITUS, EXPERIMENTAL; ENZYME ACTIVATORS; GLUCOKINASE; GLUCOSE; GLUCOSE TOLERANCE TEST; HEPATOCYTES; HOMEOSTASIS; INSULIN; INSULIN-SECRETING CELLS; KINETICS; LIVER; MALE; MICE; MICE, INBRED C57BL; OBESITY; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; THIADIAZOLES;

EID: 84895739502     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088431     Document Type: Article

References (26)

1. Schenk S, Saberi M, Olefsky JM (2008) Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 118: 2992-3002.
2. Donath MY, Ehses JA, Maedler K, Schumann DM, Ellingsgaard H, et al. (2005) Mechanisms of beta-cell death in type 2 diabetes. Diabetes 54 Suppl 2: S108-113. (Pubitemid 43343338)
3. Moller DE (2012) Metabolic disease drug discovery- "hitting the target" is easier said than done. Cell Metab 15: 19-24.
4. Riddle MC (2008) Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor. Diabetes Care 31 Suppl 2: S125-130.
5. Matschinsky FM (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8: 399-416.
6. Bouche C, Serdy S, Kahn CR, Goldfine AB (2004) The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev 25: 807-830. (Pubitemid 39362297)
7. Matschinsky FM, Zelent B, Doliba N, Li C, Vanderkooi JM, et al. (2011) Glucokinase activators for diabetes therapy: May 2010 status report. Diabetes Care 34 Suppl 2: S236-243.
8. Miller SP, Anand GR, Karschnia EJ, Bell GI, LaPorte DC, et al. (1999) Characterization of glucokinase mutations associated with maturity-onset diabetes of the young type 2 (MODY-2): different glucokinase defects lead to a common phenotype. Diabetes 48: 1645-1651. (Pubitemid 29356875)
9. Sarabu R, Bizzarro FT, Corbett WL, Dvorozniak MT, Geng W, et al. (2012) Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients. J Med Chem 55: 7021-7036.
10. Futamura M, Yao J, Li X, Bergeron R, Tran JL, et al. (2012) Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat. Diabetologia 55: 1071-1080.
11. Meininger GE, Scott R, Alba M, Shentu Y, Luo E, et al. (2011) Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 34: 2560-2566.
12. Wilding JP, Leonsson-Zachrisson M, Wessman C, Johnsson E (2013) Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes Obes Metab.
13. Lu M, Patsouris D, Li P, Flores-Riveros J, Frincke JM, et al. (2010) A new antidiabetic compound attenuates inflammation and insulin resistance in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab 298: E1036-1048.
14. O'Doherty RM, Lehman DL, Telemaque-Potts S, Newgard CB (1999) Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes 48: 2022-2027. (Pubitemid 29458366)
15. Fyfe MC, White JR, Taylor A, Chatfield R, Wargent E, et al. (2007) Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia 50: 1277-1287. (Pubitemid 46701554)
16. Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, et al. (2003) Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301: 370-373. (Pubitemid 36877072)
17. Eiki J, Nagata Y, Futamura M, Sasaki-Yamamoto K, Iino T, et al. (2011) Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. Mol Pharmacol 80: 1156-1165.
18. Pfefferkorn JA, Guzman-Perez A, Litchfield J, Aiello R, Treadway JL, et al. (2012) Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol- 1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. J Med Chem 55: 1318-1333.
19. De Ceuninck F, Kargar C, Ilic C, Caliez A, Rolin JO, et al. (2013) Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol 168: 339-353.
20. Peter A, Stefan N, Cegan A, Walenta M, Wagner S, et al. (2011) Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab 96: E1126-1130.
21. Vaxillaire M, Cavalcanti-Proenca C, Dechaume A, Tichet J, Marre M, et al. (2008) The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes 57: 2253-2257.
22. Gloyn AL, Noordam K, Willemsen MA, Ellard S, Lam WW, et al. (2003) Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 52: 2433-2440. (Pubitemid 37059517)
23. Cuesta-Munoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Nanto-Salonen K, et al. (2004) Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes 53: 2164-2168. (Pubitemid 38970771)
24. Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, et al. (1998) Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 338: 226-230. (Pubitemid 28047576)
25. Shiota M, Postic C, Fujimoto Y, Jetton TL, Dixon K, et al. (2001) Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes. Diabetes 50: 622-629. (Pubitemid 32195228)
26. Tsukita S, Yamada T, Uno K, Takahashi K, Kaneko K, et al. (2012) Hepatic glucokinase modulates obesity predisposition by regulating BAT thermogenesis via neural signals. Cell Metab 16: 825-832.